MARKHAM, ON, April 17, 2013 /CNW/ - Genitourinary cancer research in
Canada will receive additional funding thanks to a new research
collaboration between the Canadian Urologic Oncology Group (CUOG) and
Astellas Pharma Canada, Inc. (Astellas).
This year, Astellas has pledged $50,000 to further Canadian
investigators' peer-reviewed research into finding medicines and cures
for urological disorders, focusing specifically on prostate cancer.
The CUOG/Astellas Research Awards in prostate cancer will range between $10,000 and $25,000 each,
depending on the number of applicants received, and are in addition to
Astellas' multi-year commitment to the Canadian urology community
through the CUA Astellas Research Grant program.
"For over 20 years, the Canadian Urologic Oncology Group has promoted
research by students, residents and fellows through annual CUOG awards.
Under the supervision of CUOG members, students have conducted research
that has led to some extremely valuable findings and, in many cases,
served as the foundation for larger projects and research careers,"
says Dr. Fred Saad, Chair of the National Cancer Institute of Canada
G-U Group and the Canadian Urologic Oncology Group. "We are very
pleased to be able to increase the amount of money available for CUOG
awards due to additional funding provided by Astellas Pharma Canada."
Urology continues to be a priority therapeutic area for Astellas and the
company is proud to support the efforts of the Canadian urology
community through its ongoing contributions to investigator research
and patient programs.
"Innovations that result from discovery research can potentially have a
great impact on patients in the future," says Michael Tremblay,
President, Astellas Pharma Canada. "We are honoured to contribute to
advancing uro-oncology research, with the hope that one day it will
produce a cure for genitourinary cancers."
Applications for the CUOG/Astellas Research Awards are due May 1, 2013 and the recipients will be announced at the annual
CUOG meeting on June 22.
For more information, please visit CUOG's website, www.cuog.org.
About the Canadian Urologic Oncology Group (CUOG)
The Canadian Urologic Oncology Group (CUOG) is a clinical research
investigator network of leading academic and community based
urologists, medical oncologists, and radiation oncologists, committed
to furthering genitourinary (GU) cancer research in Canada.
CUOG pursues clinical trials in concert with the pharmaceutical industry
to find medicines and cures to tackle urological disorders including,
but not restricted to:
More information about CUOG can be found at www.cuog.org.
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a
Canadian affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a
pharmaceutical company dedicated to improving the health of people
around the world through the provision of innovative and reliable
The organization is committed to becoming a global category leader in
focused areas by combining outstanding R&D and marketing capabilities.
In Canada, Astellas has an intense commercial focus on five therapeutic
areas - Urology, Immunology, Infectious Disease, Dermatology and
For more information about Astellas Pharma Canada, Inc., please visit
the corporate website: www.astellas.ca
SOURCE: Astellas Pharma Canada, Inc.
For further information:
Astellas Pharma Canada, Inc.